DrugsNews.net

Drugs Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Pneumobase.it

Patients undergoing cataract surgery: Risperidone and Paliperidone associated with risk of intraoperative floppy iris syndrome


Cases of intraoperative floppy iris syndrome ( IFIS ) during cataract surgery have been reported in patients taking the atypical antipsychotics Risperidone ( Risperdal ) or Paliperidone ( Invega ). IFIS may increase the risk of eye complications during and after cataract surgery.

Intraoperative floppy iris syndrome is a complication observed during cataract surgery that was first described in 2005 in association with the alpha-1 adrenergic antagonist Tamsulosin.
Alpha-1 adrenergic receptors are present in the iris dilator muscle of the eye, where inhibition of the receptors relaxes this muscle causing a floppy iris and miosis.

Intraoperative floppy iris syndrome is characterised by a triad of intraoperative signs that may present with varying degrees of severity: billowing of a flaccid iris stroma; progressive intraoperative pupil constriction; propensity for iris prolapse towards the phaco and side port incisions.
Complications of IFIS during cataract surgery include: iris trauma; posterior capsule rupture; and vitreous loss. Postoperative complications include increased intraocular pressure and cystoid macular oedema.

Cases of IFIS associated with the use of antipsychotic agents that have alpha-1 adrenergic receptor-blocking activity have been reported in the literature. Risperidone is an atypical antipsychotic with alpha1-adrenergic antagonist actions.
A review of postmarketing safety data identified six cases of intraoperative floppy iris syndrome during cataract surgery reported for Risperidone worldwide. In two of these cases a causal relation between Risperidone and IFIS is plausible. In both these cases, the patients had no history of taking other alpha1-adrenergic antagonists. Both patients had received long-term treatment with Risperidone and developed typical features of IFIS during cataract surgery. One patient continued treatment with Risperidone and subsequently experienced a second episode of intraoperative floppy iris syndrome during cataract surgery on the second eye 4 months later.

To date, no cases of intraoperative floppy iris syndrome have been reported for Paliperidone; however, this drug is an active metabolite of Risperidone and has alpha1-adrenergic antagonist actions. Therefore, this information and advice applies also to Paliperidone.

Advice for healthcare professionals

Primary-care physicians should document the use of alpha1-adrenergic antagonists, including Risperidone and Paliperidone—when making a referral for cataract surgery.

When taking a medication history before cataract surgery, patients should be questioned about current or past use of Risperidone or Paliperidone.

Cataract surgeons should approach surgery with caution in people with such a medication history. If intraoperative floppy iris syndrome is suspected, measures to prevent the iris from prolapsing during cataract surgery may be required.

The potential benefit of stopping Risperidone or Paliperidone before cataract surgery on the risk of intraoperative floppy iris syndrome has not been established and must be weighed against the risk of stopping antipsychotic therapy. ( Xagena )

Source: Drug Safety Update 2013; Vol 7, Issue 4: A6

XagenaMedicine_2013



Indietro